Defining and treating high-risk multiple myeloma

Multiple myeloma (MM) is more recently being recognized as a heterogeneous group of disease with variability in outcomes based on specific clinical and biologic predictors. MM patients can be broadly categorized into standard, intermediate and high risk for disease relapse, morbidity and mortality....

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2015-11, Vol.29 (11), p.2119-2125
Main Authors: Usmani, S Z, Rodriguez-Otero, P, Bhutani, M, Mateos, M-V, Miguel, J S
Format: Article
Language:English
Subjects:
631/67/1059/99
631/67/1990/804
692/308/2779/109
692/700/1750
692/700/565
Cancer Research
Care and treatment
Chromosome Aberrations
Clonal deletion
Comorbidity
Complications and side effects
Critical Care Medicine
Development and progression
Gene deletion
Gene expression
Gene Expression Profiling
Health risks
Hematology
Hematopoietic Stem Cell Transplantation
Humans
Intensive
Internal Medicine
Leukemia
Medicine
Medicine & Public Health
Morbidity
Multiple myeloma
Multiple Myeloma - etiology
Multiple Myeloma - genetics
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Oncology
Patient outcomes
Patients
Plasma cell leukemia
review
Risk
Risk groups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple myeloma (MM) is more recently being recognized as a heterogeneous group of disease with variability in outcomes based on specific clinical and biologic predictors. MM patients can be broadly categorized into standard, intermediate and high risk for disease relapse, morbidity and mortality. The high-risk features include patient-specific factors such as old age, poor performance status and comorbidities; clinical features such as primary plasma cell leukemia and extramedullary disease; disease-specific biologic features such as deletion 17p, t(4;14) and high-risk gene expression profiling signatures. The current paper reviews the available data on best therapeutic approaches for high-risk MM.
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2015.209